Regeneron is one of multiple pharmaceutical and biotech firms that is working on possible treatments for COVID-19 and it announced recently that its "antibody cocktail therapy" could enter "human clinical studies by early summer." Coronavirus Response Potential Regeneron all the way back on February 4—which seems like years ago at this point—announced that it expanded its agreement with the U.S. Department of Health and Human Services to "develop new treatments combating the novel coronavirus." The company has a recent track record in these outbreak scenarios since its investigational Ebola treatment demonstrated positive clinical data in 2019.